Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
European shares set for second week of gains

2018-07-13 reuters
LONDON (Reuters) - European shares opened higher on Friday, set for a second week of gains as fears of a full-blown trade war were kept in check and optimism about the next season of corporate earnings continued to grow.
GMHLF GMHLY

112
SDPI / Superior Drilling Products, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-06-14 fintel.io
Superior Drilling Products, Inc. (AMEX:SDPI) has 25 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 6,428,637 shares. Largest shareholders include Lone Star Value Management LLC, FMR LLC / Fidelity, Adirondack Research & Management Inc., GAM Holding AG, Renaissance Technologies LLC, Vanguard Group Inc, Woodstock Corp, Acadian Asset Management Llc, Goldman Sachs Group Inc, and Bridgeway Capital Management Inc.
PRTO GS.PRB GS.PRA GALPW STML GMHLY GS GLSSP GALE GMHLF GALEW JBK GSC GS.PRICL TFG SDPI SPDI GSJ GS.PRJ GS.PRI GS.PRD GS.PRC GJS GS.PRN GS.PRK

55
ACFC / Atlantic Coast Financial Corp. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-06-11 fintel.io
Atlantic Coast Financial Corp. (NASDAQ:ACFC) has 64 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 9,478,307 shares. Largest shareholders include FJ Capital Management LLC, PL Capital Advisors, LLC, RMB Capital Management, LLC, Mendon Capital Advisors Corp, Vanguard Group Inc, GAM Holding AG, Gabelli Securities, Inc.
ABCB VBLT ACFC GALPW GALE AFCF GMHLF VBLTF STML GALEW GMHLY

1
Tesla Bonds Are in Free Fall - Bloomberg

2018-03-29 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
DHIL GMHLF GMHLY

1
Tesla bonds down to 86 US cents, start to flash warning signals

2018-03-29 themalaymailonline
The logo of Tesla is seen in Taipei October 7, 2017. — Reuters picNEW YORK, March 29 — Elon Musk’s creditors are suddenly having a serious bout of buyer’s remorse.
DHIL GMHLF GMHLY

12
Julius Baer: Unique Business Profile Isn't Fully Reflected On Valuation

2018-03-13 seekingalpha
It has good growth prospects, strong capitalization and high profitability, which aren’t currently fully reflected in its valuation.
MS.PRI MS.PRK MS.PRE MS.PRF MS.PRG 3772 MS MS.PRA GMHLF GMHLY

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 36143A109